It has been earlier shown that melanoma patients with a high stromal HGF level had a poorer response to treatment with vemurafenib, an inhibitor of BRAFV600E, used alone or in combination with trametinib, an inhibitor of MEK1/2, than those lacking HGF [103]. Here, MAP2K1 is linked to melanoma.